Dermatologische Praxis Dr. med. Abdou Zarzour
- Address
- Grosse Steinstrasse 12, 06108 Halle, Germany
Skin and Connective Tissue Diseases
The Dermatologische Praxis Dr. med. Abdou Zarzour conducts focused studies on skin and connective tissue diseases, primarily investigating chronic spontaneous urticaria and cold induced urticaria to evaluate emerging treatments.
- Long‑term efficacy and safety of remibrutinib in chronic spontaneous urticaria
- Pharmacokinetic and pharmacodynamic profiling of GTX‑B001 in inducible urticaria
- Randomized withdrawal design to assess relapse rates and treatment durability
By testing innovative oral inhibitors such as remibrutinib and novel compounds like GTX‑B001, the site seeks to improve symptom control and assess long‑term safety for patients with urticaria.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Granular Therapeutics Limited1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dermatologische Praxis Dr. med. Abdou Zarzour
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Efficacy, Safety, and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria: An Extension Study for Phase 3 Completers | Novartis Pharma AG | Phase III | Not Recruiting | Jan 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Remibrutinib | 1 | Unknown | 2023-01-24 | 2023-01-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.